Tau Hyperphosphorylated Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Description: Neurons containing abnormally hyperphosphorylated tau protein, forming neurofibrillary tangles (NFTs) characteristic of Alzheimer's disease and related tauopathies.
Tau-hyperphosphorylated neurons contain neurofibrillary tangles (NFTs), one of the two hallmark protein aggregates in Alzheimer's disease. The progressive spread of tau pathology correlates strongly with cognitive decline and represents a therapeutic target.
- Microtubule binding: Stabilizes axonal microtubules
- Isoforms: 6 isoforms in human brain (2N4R, 2N3R, 2N2R, 1N4R, 1N3R, 1N2R, 0N4R, 0N3R, 0N2R)
- Phosphorylation sites: 85 potential sites
- Post-translational modifications: Phosphorylation, acetylation, truncation
Pathological kinases:
- GSK-3β: Major tau kinase
- CDK5: Proline-directed kinase
- MAPK: Mitogen-activated protein kinases
- AMP: Adenosine monophosphate-activated protein kinase
Phosphatase dysfunction:
- PP2A: Primary tau phosphatase (70% activity)
- Hyperphosphorylation: 3-4 fold increase in phosphorylation
- Conformational change: Pathological folding
- Oligomerization: Soluble toxic oligomers
- Fibrillization: Paired helical filaments
- Aggregation: Insoluble NFTs
- Synaptic dysfunction: Loss of dendritic spines
- Axonal transport impairment: Reduced microtubule binding
- Mitochondrial dysfunction: Energy deficit
- ER stress: Unfolded protein response
- Autophagy impairment: Reduced clearance
- Stage I-II: Locus coeruleus, transentorhinal cortex
- Stage III-IV: Limbic regions (hippocampus, entorhinal)
- Stage V-VI: Isocortical areas
- Entorhinal cortex: Earliest involvement
- Hippocampal CA1: Prominent tangles
- Layer V pyramidal neurons: Cortical involvement
- Subcortical nuclei: Locus coeruleus, dorsal raphe
- NFT burden: Correlates with cognitive decline
- Biomarker: CSF tau, PET tracers
- Therapeutic target: Anti-tau immunotherapies
- CBD: Corticobasal degeneration
- PSP: Progressive supranuclear palsy
- FTD: Frontotemporal dementia
- AGD: Argyrophilic grain disease
- iPSC-derived neurons: From tauopathy patients
- Gene-edited lines: P301L, P301S mutations
- Primary neurons: Tau overexpression
- Transgenic mice: rTg4510, MAPT P301L
- AAV models: Wild-type and mutant tau
- Seeding models: Preformed fibril injection
- Active vaccines: AADvac1, ACI-35
- Passive antibodies: Gosuranemab, semorinemab, tilavonemab
- GSK-3β inhibitors: Tideglusib, lithium
- CDK5 inhibitors: In development
- Small molecules: Methylene blue derivatives
- Natural compounds: Epigallocatechin gallate
The study of Tau Hyperphosphorylated Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tau hyperphosphorylation mechanisms (2018)
- NFT formation and spread (2019)
- Anti-tau clinical trials (2022)
- Tau PET imaging (2021)